July 26, 2019 / 2:19 PM / 3 months ago

AbbVie does not expect to divest new psoriasis drug

(Reuters) - AbbVie Inc (ABBV.N) said on Friday it does not expect the Federal Trade Commission would require divestiture of its recently approved psoriasis drug Skyrizi in connection with the company’s $63 billion pending deal to buy Allergan Plc (AGN.N).

The company hopes Skyrizi will help it retain share in the psoriasis treatment market, as sales of its top-selling drug Humira face pressure from competition in Europe and could come under pressure in the United States starting 2023.

AbbVie expects Skyrizi sales of about $250 million in 2019, executives said on a conference call.

Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below